Alex Delaney-Gesing


Oxurion NV doses first patient in study of THR-687 as DME treatment

Oxurion NV announced Wednesday the first patient to be dosed in the INTEGRAL phase 2 clinical study evaluating THR-687 as a treatment for patients with DME.

Analyzing real-world registry study of YUTIQ for chronic non-infectious posterior uveitis

Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.

Aerie reports positive phase 3 results for netarsudil 0.02% vs ripasudil 0.4% in lowering IOP

Aerie Pharmaceuticals announced Tuesday positive topline results for the phase 3 trial evaluating netarsudil 0.02% versus ripasudil 0.4% for the treatment of open-angle glaucoma and elevated IOP.